Boukhvalova Marina S, Prince Gregory A, Soroush Layla, Harrigan Dolores C, Vogel Stefanie N, Blanco Jorge C G
Virion Systems, Inc. 9610 Medical Center Drive, Suite 100 Rockville, MD 20850, USA.
Vaccine. 2006 Jun 5;24(23):5027-35. doi: 10.1016/j.vaccine.2006.03.064. Epub 2006 Apr 18.
Formalin-inactivated respiratory syncytial virus vaccine (FI-RSV) induces a poorly understood immunopathological response that leads to disease enhancement upon RSV infection of vaccinees. In the cotton rat model, inclusion of monophosphoryl lipid A (MPL) in the FI-RSV formulation was found to mitigate the lung pathology associated with vaccine-enhanced disease. Here we report that the protective effect of MPL on FI-RSV vaccine-enhanced disease is associated with a dramatic reduction in levels of Th1- and Th2-type cytokines and chemokines normally elicited in response to RSV challenge. Our data illustrate the complexity of proinflammatory response elicited by FI-RSV vaccination and RSV infection and the potential importance of MPL in modifying this response.
福尔马林灭活呼吸道合胞病毒疫苗（FI-RSV）会引发一种尚不清楚的免疫病理反应，这种反应会导致接种疫苗者在感染呼吸道合胞病毒后病情加重。在棉鼠模型中，研究发现FI-RSV制剂中加入单磷酰脂质A（MPL）可减轻与疫苗增强型疾病相关的肺部病理变化。在此我们报告，MPL对FI-RSV疫苗增强型疾病的保护作用与通常在应对呼吸道合胞病毒攻击时引发的Th1型和Th2型细胞因子及趋化因子水平的显著降低有关。我们的数据说明了FI-RSV疫苗接种和呼吸道合胞病毒感染引发的促炎反应的复杂性，以及MPL在改变这种反应方面的潜在重要性。
